149 related articles for article (PubMed ID: 37661909)
21. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
Carvajal RD; Butler MO; Shoushtari AN; Hassel JC; Ikeguchi A; Hernandez-Aya L; Nathan P; Hamid O; Piulats JM; Rioth M; Johnson DB; Luke JJ; Espinosa E; Leyvraz S; Collins L; Goodall HM; Ranade K; Holland C; Abdullah SE; Sacco JJ; Sato T
Nat Med; 2022 Nov; 28(11):2364-2373. PubMed ID: 36229663
[TBL] [Abstract][Full Text] [Related]
22. Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations.
Montazeri K; Pattanayak V; Sullivan RJ
Drug Des Devel Ther; 2023; 17():333-339. PubMed ID: 36785760
[TBL] [Abstract][Full Text] [Related]
23. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
[TBL] [Abstract][Full Text] [Related]
24. Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma.
Fahmy LM; Schreidah CM; McDonnell DE; Carvajal RD; Magro CM; Geskin LJ
Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478664
[TBL] [Abstract][Full Text] [Related]
25. Review of bi-specific therapies in uveal melanoma.
Orloff M; Seedor R; Sato T
Cancer Gene Ther; 2022 Dec; 29(12):1814-1818. PubMed ID: 35236927
[TBL] [Abstract][Full Text] [Related]
26. Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond.
Gerard C; Shum B; Nathan P; Turajlic S
Immunooncol Technol; 2023 Sep; 19():100386. PubMed ID: 37483658
[TBL] [Abstract][Full Text] [Related]
27. [New drug approval: Tebentafusp for treatment of metastatic uveal melanoma HLA A*02:01-positive patients].
Gaillard A; Matet A; Rodrigues M
Bull Cancer; 2023 Jan; 110(1):9-10. PubMed ID: 36357199
[No Abstract] [Full Text] [Related]
28. Sepsis-like cytokine release syndrome after application of tebentafusp in metastasized uveal melanoma.
Geidel G; Abeck F; Hansen I; Kött J; Heidrich I; Rünger A; Hildebrandt L; Gebhardt C
J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):e473-e475. PubMed ID: 38059699
[No Abstract] [Full Text] [Related]
29. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.
Petzold A; Steeb T; Wessely A; Koch EAT; Vera J; Berking C; Heppt MV
Cancer Treat Rev; 2023 Apr; 115():102543. PubMed ID: 36931146
[TBL] [Abstract][Full Text] [Related]
30. Ensuring equity in the era of HLA-restricted cancer therapeutics.
Smithy JW; Blouin A; Diamond LC; Postow M
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36442912
[TBL] [Abstract][Full Text] [Related]
31. Treatment of metastatic uveal melanoma in 2022: improved treatment regimens and improved prognosis.
Reichstein D; Brock A; Lietman C; McKean M
Curr Opin Ophthalmol; 2022 Nov; 33(6):585-590. PubMed ID: 36094043
[TBL] [Abstract][Full Text] [Related]
32. Uveal melanoma: In the era of new treatments.
Wespiser M; Neidhardt E; Negrier S
Cancer Treat Rev; 2023 Sep; 119():102599. PubMed ID: 37473516
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous adverse effects induced by tebentafusp in patients with metastatic uveal melanoma: a case series and treatment insights.
Rodriguez I; Norman T; Guenther J; Smart K; Kwong A; Berry J; In GK; Worswick S
Clin Exp Dermatol; 2024 Mar; 49(4):392-394. PubMed ID: 37956104
[No Abstract] [Full Text] [Related]
34. From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma.
Synoradzki KJ; Paduszyńska N; Solnik M; Toro MD; Bilmin K; Bylina E; Rutkowski P; Yousef YA; Bucolo C; Zweifel SA; Reibaldi M; Fiedorowicz M; Czarnecka AM
Curr Oncol; 2024 Feb; 31(2):778-800. PubMed ID: 38392052
[TBL] [Abstract][Full Text] [Related]
35. Evolving Management of Stage IV Melanoma.
Switzer B; Piperno-Neumann S; Lyon J; Buchbinder E; Puzanov I
Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e397478. PubMed ID: 37141553
[TBL] [Abstract][Full Text] [Related]
36. First Drug Approved for Rare Eye Cancer.
Cancer Discov; 2022 Apr; 12(4):879-880. PubMed ID: 35115315
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapies for the Treatment of Uveal Melanoma-History and Future.
Schank TE; Hassel JC
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31344957
[TBL] [Abstract][Full Text] [Related]
38. Drug-induced photosensitivity during tebentafusp treatment for metastatic uveal melanoma: A newly described occurrence.
Lambertini M; Comito F; Melotti B; Baracca MF; Dika E
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):e207-e208. PubMed ID: 36177547
[No Abstract] [Full Text] [Related]
39. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
